Literature DB >> 24684546

Hypertriglyceridemia and low high-density lipoprotein cholesterolemia are associated with increased hazard for urolithiasis.

Ho Won Kang1, Sang Keun Lee, Won Tae Kim, Yong-June Kim, Seok-Joong Yun, Sang-Cheol Lee, Wun-Jae Kim.   

Abstract

PURPOSE: To assess the association between dyslipidemia and urolithiasis, a propensity score-matching study was performed. PATIENTS AND METHODS: Fasting blood samples were taken, and serum lipid profiles were measured in 655 stone formers (SF) and 1965 propensity score-matched controls between 2005 and 2011. The controls, from a health-screening program, did not have a history of dyslipidemia or statin use and have any evidence of stone disease, as determined by abdominal radiography, ultrasonography examination. Propensity score-matching with respect to age, sex, and body mass index was used to minimize selection bias, and the logistic regression analysis was adjusted for other components of metabolic syndrome.
RESULTS: Compared with controls, the SF group had significantly higher mean triglyceride and lower total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol levels (each P<0.001). The SF group was also more likely to have hypertriglyceridemia and low HDL-cholesterolemia, and less likely to have hypercholesterolemia and high LDL cholesterolemia compared with controls (each P<0.05). When adjusted for other components of metabolic syndrome including obesity, presence of diabetes mellitus or hypertension, the odds ratio (OR) for urinary stones appeared with hypercholesterolemia (OR=0.747, P=0.003), hypertriglyceridemia (OR=1.901, P<0.001), low HDL cholesterolemia (OR=1.886, P<0.001) and high LDL cholesterolemia (OR=0.610, P<0.001).
CONCLUSIONS: Our study implies that dyslipidemia may play a crucial part in urinary stone risk.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24684546     DOI: 10.1089/end.2014.0135

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  8 in total

1.  Lipidomics Reveals the Therapeutic Effects of EtOAc Extract of Orthosiphon stamineus Benth. on Nephrolithiasis.

Authors:  Yufan Chao; Songyan Gao; Na Li; Hongxia Zhao; Yong Qian; Haihong Zha; Wei Chen; Xin Dong
Journal:  Front Pharmacol       Date:  2020-08-21       Impact factor: 5.810

2.  Dyslipidemia is associated with an increased risk of nephrolithiasis.

Authors:  James H Masterson; Jason R Woo; David C Chang; Thomas Chi; James O L'Esperance; Marshall L Stoller; Roger L Sur
Journal:  Urolithiasis       Date:  2014-09-06       Impact factor: 3.436

3.  Impact of dyslipidemia on 24-h urine composition in adults without urolithiasis.

Authors:  Chao Cai; Zanlin Mai; Tuo Deng; Zhijian Zhao; Wei Zhu; Yaoan Wen; Xiaolu Duan; Wenqi Wu; Guohua Zeng
Journal:  Lipids Health Dis       Date:  2018-11-06       Impact factor: 3.876

4.  Decreased Associated Risk of Gout in Diabetes Patients with Uric Acid Urolithiasis.

Authors:  Chan Jung Liu; Jin Shang Wu; Ho Shang Huang
Journal:  J Clin Med       Date:  2019-09-25       Impact factor: 4.241

5.  Association between hyperlipidemia and calcium oxalate lower urinary tract uroliths in dogs.

Authors:  Mathieu V Paulin; Marilyn Dunn; Catherine Vachon; Guy Beauchamp; Bérénice Conversy
Journal:  J Vet Intern Med       Date:  2021-12-02       Impact factor: 3.333

6.  Dyslipidemia Increases the Risk of Incident Kidney Stone Disease in a Large Taiwanese Population Follow-Up Study.

Authors:  Jia-An Hung; Chien-Hsun Li; Jiun-Hung Geng; Da-Wei Wu; Szu-Chia Chen
Journal:  Nutrients       Date:  2022-03-23       Impact factor: 5.717

7.  Association between low-testosterone and kidney stones in US men: The national health and nutrition examination survey 2011-2012.

Authors:  Emre Yucel; Stacia DeSantis; Mary A Smith; David S Lopez
Journal:  Prev Med Rep       Date:  2018-04-06

8.  Elevated non-high-density lipoprotein cholesterol corresponds to a high risk of nephrolithiasis in children.

Authors:  Meiyuan Chen; Jing Xiao; Yuan Du; Miaomiao Wang; Jimeng Ruan; Ye Tian
Journal:  BMC Urol       Date:  2020-08-10       Impact factor: 2.264

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.